Anatomical Lung Resection After Neoadjuvant Chemoradiotherapy

被引:4
作者
Burrows, Whitney M. [1 ]
机构
[1] Univ Maryland, Med Ctr, Dept Thorac Surg, 22 South Green St,N4E35, Baltimore, MD 21201 USA
关键词
Stage III non-small cell lung cancer; lobectomy and pneumonectomy following chemoradiotherapy; induction/neoadjuvant chemoradiotherapy;
D O I
10.1053/j.semtcvs.2007.12.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The critical role for anatomical lung resection-segmentectomy, lobectomy, pneumonectomy-in the treatment of Stage I and II non-small cell lung cancer is undisputed. In contrast, the primacy of surgery in the management of Stage III disease is not established. Increasingly, however, the multimodality approach to locally advanced lung cancer has gained acceptance, and the integration of surgery into the treatment algorithms for Stage III cancers, particularly N2 spread, has evolved. Herein, the important steps in this evolution are defined. The concept of induction or neoadjuvant chemoradiotherapy followed by resection is emphasized, and evidence supporting surgery's therapeutic value in this schema is provided. Our center's strategy for the successful and safe delivery of trimodality care is comprehensively outlined. © 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:360 / 365
页数:6
相关论文
共 24 条
[1]   CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[2]  
Albain KS, 2005, J CLIN ONCOL, V23, p16S
[3]   Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications [J].
Andre, F ;
Grunenwald, D ;
Pignon, JP ;
Dujon, A ;
Pujol, JL ;
Brichon, PY ;
Brouchet, L ;
Quoix, E ;
Westeel, V ;
Le Chevalier, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2981-2989
[4]   Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial [J].
Betticher, DC ;
Schmitz, SFH ;
Tötsch, M ;
Hansen, E ;
Joss, C ;
von Briel, C ;
Schmid, RA ;
Pless, M ;
Habicht, J ;
Roth, AD ;
Spiliopoulos, A ;
Stahel, R ;
Weder, W ;
Stupp, R ;
Egli, F ;
Furrer, M ;
Honegger, H ;
Wernli, M ;
Cerny, T ;
Ris, HB .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1752-1759
[5]   Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival [J].
Bueno, R ;
Richards, WG ;
Swanson, SJ ;
Jaklitsch, MT ;
Lukanich, JM ;
Mentzer, SJ ;
Sugarbaker, DJ .
ANNALS OF THORACIC SURGERY, 2000, 70 (06) :1826-1831
[6]  
DEUTSCH M, 1994, CANCER, V74, P1243, DOI 10.1002/1097-0142(19940815)74:4<1243::AID-CNCR2820740411>3.0.CO
[7]  
2-D
[8]  
Dillman R, 1966, JNCI-J NATL CANCER I, V88, P1175
[9]   One hundred consecutive pneumonectornies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits [J].
Doddoli, C ;
Barlesi, F ;
Trousse, D ;
Robitail, S ;
Yena, S ;
Astoul, P ;
Giudicelli, R ;
Fuentes, P ;
Thomas, P .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (02) :416-425
[10]  
Eberhardt W, 2004, LUNG CANCER-J IASLC, V46, pS40